Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

37 results about "Obesity associated disorder" patented technology

Depression, anxiety, and other mood disorders are associated with both eating disorders and obesity. Adolescents who are depressed may be at an increased risk of becoming obese.

Bacterial strain as well as composition and application

The invention discloses a bacterial strain as well as a composition and application, and relates to the technical field of strain separation and application. The Cristinia sp. provided by the invention can be applied to treatment or prevention of liver function impairment and liver function impairment related diseases, alimentary canal mucosal injury and alimentary canal mucosal injury related diseases, diabetes, obesity and obesity related diseases. The inventor verifies that the Cristinia sp. provided by the invention has no toxic or side effect on the kidney and can reduce the weight of the liver; the initial steatohepatitis focus can be treated; fat accumulation of liver cells can be slowed down; AST and ALT in serum can be reduced; and abdominal white fat inflammatory lesion can be reduced. The Cristinia sp. can also repair the digestive tract mucosa, recover the barrier function of the mucosa, and prevent and treat intestinal leakage, peptic ulcer and other diseases caused by barrier function impairment. The Cristinia sp. also has the effects of reducing fasting blood-glucose of a body, regulating insulin level and reducing body fat of mammals, and has the effects of preventing and treating diabetes and improving the metabolic function of obese patients.
Owner:MOON (GUANGZHOU) BIOTECH CO LTD

Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity

The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular cannabinoid CB?1#191 receptor antagonist / inverse agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders.
Owner:MERCK SHARP & DOHME CORP

Leg1 protein and application thereof in obesity-related diseases

ActiveCN106749601APromotes synthesis and accumulationSynthetic accumulation inhibitionPeptide/protein ingredientsMetabolism disorderDiseaseResearch Object
The invention provides a Leg1 protein and application thereof in obesity-related diseases, relating to the technical field of functions and application of genes. By using an mLeg1-gene knockout mouse as the research object, means of genetics, molecular biology, biochemistry and cytobiology are utilized to perform very comprehensive research on the functions of the mLeg1 gene. The research result indicates that the mLeg1 protein (SEQ ID NO.2) and homologous proteins thereof (SEQ ID NO.1 and SEQ ID NO.5-8) and coding genes thereof can be used as brand-new targets for synthesizing related drugs from fat, can be used in the fields of preparation of drugs for treating obesity or losing weight, preparation of drugs for treating fat deficiency or increasing weight, preparation or screening of drugs for treating diabetes and preparation of drugs for adjusting fat accumulation of vertebrates and other related drugs for adjusting fat synthesis, and provides a brand-new idea for developing and researching drugs for adjusting internal fat synthesis and accumulation of vertebrates or treating fat-related diseases.
Owner:ZHEJIANG UNIV

Bicyclic pyranone derivatives and methods of use thereof

InactiveUS20110243940A1BiocideNervous disorderDiabetic complicationBicyclopyrone
The present invention relates to Bicyclic Pyranone Derivatives, their compositions and uses for treating or preventing a metabolic disorder, dyslipidemia, a cardiovascular disease, a neurological disorder, a hematological disease, cancer, inflammation, a respiratory disease, a gastroenterological disease, diabetes, a diabetic complication, obesity, an obesity-related disorder or non-alcoholic fatty liver disease. Formula (I). Y is —C— when an optional and additional bond is present and Y is —CH— when an optional and additional bond is not present; Z is —O—, —NH— or —N(alkyl)- when the optional and additional bond between Y and Z Is absent, and Z Is —N— when the optional and additional bond between Y and Z is present; R1 is H1 halo or —CN; R2 is alkyl, alkenyl or -(alkyleneVcydoalkyl; t is 0 or 1; R3 is O when the optional and additional bond between Y and R3 is present, and R3 is alkyl.haloalkyl.—C(0)0R5.-alkylene-O-alkyt or —O-alkyl when the optional and additional bond between Y and R3 is absent: R4 is H, alkyl or aryl, wherein an aryl group can be unsubstituted or optionally substituted.
Owner:SCHERING CORP

Method and system for treating obesity-related diseases by oral active AdipoRon

PendingCN114073667ASimplify treatment effect experimentsLow costMetabolism disorderPharmaceutical delivery mechanismDiseaseLow glucose
The research is different from other previous researches, and the action mechanism of the AdipoRon for treating the type 2 diabetes mellitus is discussed by applying a biological method. Liver cells are taken as experimental subjects, an experimental group for blocking a P13 / Akt signal channel is constructed, then AdipoRon is given, expression of saccharide genes related to the liver cells is analyzed, and the cellular mechanism of the AdipoRon for treating type 2 diabetes mellitus is discussed. At present, the research is not reported at home and abroad. The current method for treating the type 2 diabetes mellitus almost needs reasonable diet and exercise, and generates adverse effects such as hypoglycemia and weight gain, and the excessive caloric intake can be safely reduced by orally taking the AdipoRon, and the consequence caused by the lifestyle of sedentariness can be relieved, so that the AdipoRon provides a novel treatment method. By using the method, lots of expenditures for purchasing db / db mice and double-gene knockout mice can be saved.
Owner:WENZHOU MEDICAL UNIV

Application of human Nectin-2 protein

Provided are uses of human Nectin-2 protein. Nectin-2 protein, derived protein thereof or modified protein thereof can effectively inhibit obesity and diabetes, and are also used to treat obesity-related diseases including hypertension, and hyperlipemia, etc. The Nectin-2 protein not only reduces blood glucose, but also improves the body glucose metabolism, and enhances sensitivity to tissue insulin by improving energy metabolism of the body, and improves adaptability to cold stimulation by activating fatty acid metabolism of the body.
Owner:BEIJING VDJBIO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products